| abstract |
The present invention is based on in vivo validation where RSV is inhibited by intranasal administration of the iRNA agent and parenteral administration of the iRNA agent. It has also been shown that effective virus reduction can be achieved by treating one or more viruses simultaneously. Based on such findings, the present invention provides general and specialized compositions and methods useful for reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, eg, a mammal such as a human. . These findings can be applied to other respiratory viruses. |